Skip to main content

Longitudinal pattern of pain medication utilization in peripheral neuropathy patients.

Citation
Callaghan, B. C., et al. “Longitudinal Pattern Of Pain Medication Utilization In Peripheral Neuropathy Patients.”. Pain, pp. 592-599.
Center University of Michigan
Author Brian C Callaghan, Evan Reynolds, Mousumi Banerjee, Kevin A Kerber, Lesli E Skolarus, James F Burke
Abstract

We aimed to investigate the pattern and utilization of neuropathic pain medications in peripheral neuropathy patients. Using a privately insured, health care claims database from 2001 to 2014, we identified a retrospective cohort of incident peripheral neuropathy patients (validated ICD-9 definition) after excluding other chronic pain conditions. Outcome measures included opioid prescriptions, chronic opioid therapy (greater than or equal to 90 days of continuous supply), guideline-recommended medications for painful peripheral neuropathy (serotonin reuptake inhibitors, tricyclic antidepressants, and gabapentinoids), and pain specialists (neurologists, physiatrists, and anesthesiologists). Multivariable logistic regression was used to evaluate associations of patient-level factors with these outcomes. The peripheral neuropathy population included 14,426 individuals with a mean (SD) age of 43.1 years (2.8) and 52.4% men followed for 3.1 (1.7) years before and 4.5 (1.4) years after the diagnosis. In this population, 65.9% received ≥1 opioid prescription, and 8.8% received chronic opioid therapy. Of those receiving chronic opioid therapy, only 26.4% received a guideline-recommended medication before chronic opioid status. For guideline-recommended medications, 35.7% received ≥1, 12.4% ≥2, and 3.8% ≥3 different medications. No patient-level factors were associated with both high opioid utilization (initiation and chronic use) and low guideline-recommended medication utilization. Pain specialists were associated with high opioid utilization and high guideline-recommended medication utilization. In conclusion, opioid initiation and transition to chronic opioid therapy are frequent in a peripheral neuropathy population despite few patients receiving more than one guideline-recommended medication. Efforts to decrease opioid utilization and increase guideline-recommended medication use are needed to improve current neuropathic pain treatment.

Year of Publication
2019
Journal
Pain
Volume
160
Issue
3
Number of Pages
592-599
Date Published
03/2019
ISSN Number
1872-6623
DOI
10.1097/j.pain.0000000000001439
Alternate Journal
Pain
PMID
30418352
PMCID
PMC6377284
Download citation